2-((2-(1H-pyrrolo(2,3-b)pyridin-3-yl)pyrimidin-4-yl)amino)-2-methyl-N-(2,2,2-trifluoroethyl)butanamide

Janus kinase 3 ; Homo sapiens







5 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 26473751 VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis. 2016 Jan 3
2 25385260 A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis. 2015 Feb 1
3 25762693 VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease. 2015 May 3
4 24818516 Selective JAK inhibitors in development for rheumatoid arthritis. 2014 Aug 1
5 23055694 Kinase inhibitors: a new class of antirheumatic drugs. 2012 1